louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03600272: Comparison of Combined Spinal-epidural Analgesia Versus Epidural Analgesia for Pain Management During Labor
Official title: Comparison of Combined Spinal-epidural Analgesia Versus Epidural Analgesia During Labor
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Labor Long
Labor Pain
Labor Fetal Anoxia
Keywords: Combined spinal-epidural analgesia
Epidural analgesia
Labor duration
Lead sponsor: Tongji Hospital
Sponsor class: OTHER
Collaborators: name: Tongji Hospital
First posted: 2018-07-26
Enrollment: 200
Sex: FEMALE
Minimum age (years): 15
Maximum age (years): 50
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Participants who request neuraxial labor analgesia are randomly assigned into two groups by a computer-generated random number table using Excel. One group received combined spinal-epidural analgesia during labor, the other group received epidural analgesia during labor.
Primary purpose: TREATMENT

Brief summary: The investigators want to compare the safety and efficacy between the combined spinal-epidural analgesia and epidural analgesia during labor.

Detailed description: Participants who request neuraxial labor analgesia are randomized to receive combined spinal-epidural analgesia or epidural analgesia during labor. The investigators collect the data on the duration of three stages of labor, the mode of delivery, neonatal Apgar scores, VAS scores, modified Bromage scores.

Eligibility criteria: Inclusion Criteria:

* Healthy women at term (37 to 42 weeks of gestation), vertex presentation, singleton pregnancy who desired vaginal delivery were eligible to participate.

Exclusion Criteria:

* Contraindications to neuraxial techniques such as clinically significant coagulopathy and increased intracranial pressure, and patients with preterm labor, multiple pregnancies, non-vertex presentation, cephalopelvic disproportion and severe obstetric complications

Primary outcomes:
measure: Labor duration
timeFrame: At the end of delivery
Secondary outcomes:
measure: The mode of delivery
timeFrame: At the end of delivery
measure: 1 minute and 5 minutes Apgar scores
timeFrame: 1 min after delivery, 5 min after delivery.
measure: Visual Analogue Scores(VAS)
timeFrame: At 5min before analgesia; at 5min, 15min, 30min, 1h after the first dose of analgesic drugs； at cervical dilation of 3cm , 6cm and 10cm; at the time of birth of infant; at the time of delivery of placenta.
measure: Modified Bromage scores
timeFrame: At 5min before analgesia; at 5min, 15min, 30min, 1h after the first dose of analgesic drugs； at the cervical dilation of 3cm , 6cm and 10cm; at the time of birth of infant; at the time of delivery of placenta.
Other outcomes:
Locations:
city: Wuhan
country: China
facility: Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
state: Hubei
Study officials:
affiliation: Tongji Hospital
name: Haiyi Liu, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04490772: Characteristics and Outcomes of Gastrointestinal Manifestations of COVID-19
Official title: Characteristics and Outcomes of Gastrointestinal Manifestations of COVID-19
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Infectious
Keywords: Covid-19
characteristics
Outcome
Egypt
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2020-07-29
Enrollment: 200
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Confirmed Covid-19 with GIT manifestations

Brief summary: Patients confirmed COVID-19 with gastrointestinal manifestations will be included. Characteristics and outcomes will be described for them.

Detailed description: Patients diagnosed as confirmed Covid-19 according to WHO and Egyptian Ministry of Health and Population (MOH) definitions will be included.The following will be done for all patients:

Demographic characters; age, sex, presence of co-morbidities such as hypretension, diabetes mellitus, obstructive lung diseases, ischemic heart diseases...etc, history of contact to covid-19 patients or recent travelling abroad.Clinical Characteristics: By recording of clinical manifestation such as fever, cough, shortness of breath, sore throat, change in taste or smell, nausea,vomiting and diarrhea will be done. Complications and the type of treatment received by the patients will also be described including mechanical ventilation.

Laboratory data will also be included : blood picture, liver enzymes, ESR,CRP, serum ferritin, D-dimer and troponin.

Follow up of the patients will be done until improvement, deaths or complications to determine disease outcomes.

Eligibility criteria: Inclusion Criteria:

* Confirmed Covid-19 with GIT manifestations

Exclusion Criteria:

* Patients refuse to participate

Primary outcomes:
measure: Clinical data questionnaire
timeFrame: 2 months
measure: Tests such as CBC
timeFrame: 2 months
measure: liver function test
timeFrame: 2 months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT06738472: Efficacy of Home-Based Posture Exercises As an Addition to Pharmacological Treatment in Fibromyalgia
Official title: Efficacy of Home-Based Posture Exercises As an Addition to Pharmacological Treatment in Fibromyalgia
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Fibromyalgia
Keywords: fibromyalgia
home-based therapy
pain
quality of life
Lead sponsor: Kirsehir Ahi Evran Universitesi
Sponsor class: OTHER
First posted: 2024-12-17
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: This interventional study aimed to evaluate the effects of home exercise in addition to pharmacological treatment on pain threshold and spinal mobility in fibromyalgia patients.


Eligibility criteria: Inclusion Criteria:

* Participants were between the ages of 18 and 65,
* No diagnosis of rheumatic disease,
* No diagnosis of chronic comorbid disease,
* Participants diagnosed with fibromyalgia syndrome according to the European League Against Rheumatism (EULAR) criteria will be included as volunteers.

Exclusion Criteria:

* Patients under 18, over 65 years of age
* Those diagnosed with chronic comorbid diseases
* Those with a history of rheumatic disease

Primary outcomes:
measure: algometry
timeFrame: 4 weeks
measure: spinal mouse
timeFrame: 4 weeks
Secondary outcomes:
measure: HADS
timeFrame: 4 weeks
measure: PSQI
timeFrame: 4 weeks
measure: SF-12
timeFrame: 4 weeks
Other outcomes:
Locations:
Study officials:
References:
citation: Wu X, Liu H, Xiao H, Conway JA, Hunter E, Kappes JC. Functional RT and IN incorporated into HIV-1 particles independently of the Gag/Pol precursor protein. EMBO J. 1997 Aug 15;16(16):5113-22. doi: 10.1093/emboj/16.16.5113.
Clinical trial NCT06717672: Effect of Lidocaine in Reducing Opioids Requirement in Day Care Surgery
Official title: Efficacy of Lidocaine in Decreasing Perioperative Analgesic Opioids Requirement After Ambulatory Surgery
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Pain
Post-operative Pain Control
Post-operative Pain
Keywords: Lidocaine
Opiods
Peri-operative pain
Decrease Opioid requirement
Ambulatory surgeries
Lead sponsor: Liaquat National Hospital & Medical College
Sponsor class: OTHER
First posted: 2024-12-05
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: 1. \*Reduced opioid consumption
2. \*Decreased pain scores
3. \*Fewer opioid-related side effects
4. \*Improved patient satisfaction

Detailed description: Studies have shown that lidocaine can reduce opioid consumption by 20-50% in the perioperative period.

Studies have shown that lidocaine can reduce opioid consumption by 20-50% in the perioperative period.

By reducing opioid consumption, lidocaine can also decrease the incidence of opioid-related side effects, such as nausea, vomiting, and respiratory depression.

Lidocaine's analgesic effects can improve patient satisfaction and reduce anxiety related to pain

Eligibility criteria: Inclusion Criteria:

* ASA 1 and 2
* patient age between 18 and 65 years
* Patient undergoing ambulatory surgeries

Exclusion Criteria:

* Pregnant women
* Allergic to Lidocaine Patient who had fever and treated with antibiotic and steroid in last month

Primary outcomes:
measure: Peri-operative pain
timeFrame: at 2 hours, 4 hours, 6 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Karachi
country: Pakistan
facility: Liaquat National Hospital and Medical College
state: Sindh
Study officials:
affiliation: Liaquat National Hospital and Medical College
name: Hanesh Tanwani Dr Hanesh Tanwani
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02292472: Medytoxin® Treatment in Patients With Benign Masseteric Hypertrophy
Official title: A Randomized, Double-blind, Multi-center, Phase II Optimal Dose-finding Study to Determine Safety and Efficacy of Medytoxin® in Subjects in Benign Masseteric Hypertrophy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Hypertrophy of Masseter Muscle
Keywords: masticatory muscles
Lead sponsor: Medy-Tox
Sponsor class: INDUSTRY
First posted: 2014-11-17
Enrollment: 69
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study design is A Randomized, Double-blind, Multi-center, Phase II Optimal Dose-finding Study to Determine the Safety and Efficacy of Meditoxin® in Subjects in Benign Masseteric Hypertrophy.

Detailed description: Subjects who voluntarily signed the informed consent and are judged to be eligible for this study will be intramuscularly injected with the study drug or the placebo to find appropreate dose for the treatment of Benign Masseteric Hypertrophy. Thereafter, follow-up visits will be made and efficacy and safety assessment will be conducted.

Eligibility criteria: Inclusion Criteria:

1. Subject who shows benign masseteric hypertrophy
2. Male or female subject over 19 years of age and written informed consent is obtained from the patient or LAR.
3. Subject who has bisymmetry of masster at visual assessment.
4. Subejects who qualifies the standard meets on ultrasonics wave value.
5. Subjects who can and will comply with the requirements of the protocol.

Exclusion Criteria:

1. Diagnosis of myasthenia, facial palsy or severe facial asymmetry
2. Subject who got any treatment, including double jaw surgery, laser, thread treatment etc. in 1 year.
3. Subject who had previously received botulinum toxin within 3 months prior to the study entry
4. Subject who is participating in other investigational study at present or 30 prior to the screening date.
5. Subject with known hypersensitivity to botulinum toxin
6. Subject who are pregnant or lactating or found pregnancy though the urine or sebum test or disagreed to avoid pregnancy during study preiod.
7. Subjects who are not eligible for this study at the discretion of the investigator.

Primary outcomes:
measure: Reduction amount of masseter muscle thickness
timeFrame: after the injection
Secondary outcomes:
measure: Reduction amount of masseter muscle thickness and lower face volume
timeFrame: after the injection
measure: Overall satisfaction of subject
timeFrame: after the injection
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Chungang university hospital
Study officials:
affiliation: Chung-Ang University Hosptial, Chung-Ang University College of Medicine
name: Beom Joon Kim, Ph D
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00768872: Spinal Cord Stimulation Research Study
Official title: Neuro Ambulatory Data Recorder (ADR) Spinal Cord Stimulation (SCS) Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Chronic Low Back and Leg Pain
Keywords: activity, spinal cord stimulation, pain
Lead sponsor: MedtronicNeuro
Sponsor class: INDUSTRY
First posted: 2008-10-08
Enrollment: 66
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Candidates for Spinal Cord Stimulation

Brief summary: The purpose of this study is to characterize a patient's activity levels before and after spinal cord stimulation therapy.


Eligibility criteria: Inclusion Criteria:

* 18 years of age or older
* Candidate for SCS device trial
* Subject is ambulatory
* Diagnosed with low back pain or low back pain plus leg pain for at least 6 months
* Undergoing treatment for low back pain or low back pain plus leg pain
* Does not have or has not had a previous SCS implant
* Willing and able to complete protocol requirements
* Willing and able to sign the study-specific Informed Consent form
* Male or non-pregnant female

Exclusion Criteria:

* Have plans to enroll in another clinical study during their participation in this study, or are currently enrolled in a clinical study that could interfere in participation in the trial or affect the scientific soundness of this study
* Cancer or any other malignant disease
* Present or past diagnosis of schizophrenia or of delusional, psychotic, or dissociative disorder
* A pain-related surgery in the previous 12 weeks of enrollment, the intent to undergo surgery during the period of the study
* Non-English speaking or an inability to complete questionnaires accurately

Primary outcomes:
measure: Change from Baseline in Physical Activity (total centi-Gs per 5.125 seconds)
timeFrame: 4, 12, 24 weeks post implant
measure: Change from Baseline in Posture Parameters (minutes per 24 hours)
timeFrame: 4, 12, 24 weeks post implant
Secondary outcomes:
Other outcomes:
Locations:
city: Napa
country: United States
facility: Napa Pain Institute
state: California
city: Chestnut Hill
country: United States
facility: Brigham and Women's Hospital
state: Massachusetts
city: Edina
country: United States
facility: Medical Advanced Pain Specialists (MAPS)
state: Minnesota
Study officials:
affiliation: Medical Advanced Pain Specialists (MAPS)
name: David M Schultz, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Brigham and Women's Hospital
name: Robert Jamison, Ph.D
role: PRINCIPAL_INVESTIGATOR
affiliation: Napa Pain Institute
name: Eric Grigsby, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04715672: The Establishment of Advanced Brain Function Evaluation Model for Anterior Cruciate Ligament Reconstruction
Official title: The Establishment of Evaluation Model About Returning to Sports Post-operation of Anterior Cruciate Ligament Reconstruction by Resting State Functional Magnetic Resonance and Three-dimensional Gait Analysis
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Anterior Cruciate Ligament Reconstruction;Resting State Functional Magnetic Resonance;Three-dimensional Gait Analysis;Return to Sports
Lead sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
Sponsor class: OTHER
First posted: 2021-01-20
Enrollment: 50
Sex: ALL
Minimum age (years): 16
Maximum age (years): 50
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients post anteriorcruciate ligament (ACL) reconstruction

Brief summary: It is difficult to establish the standard of return to sports post anterior cruciate ligament (ACL) reconstruction. The amplitude of low frequency fluctuation (ALFF) and functional connectivity (FC) of resting state functional magnetic resonance imaging (fMRI) can explore the differences in neural function of different populations, but have not been applied in the study of ACL postoperative return to sports.This project intends to use ALFF algorithm to calculate the changes of BLOD signals of coppers and non- coppers after ACL surgery in the subfrequency band and the functional network in the subfrequency band, explore the relationship between the default network (DMN) and the sensorimotor network (SMN), and use three-dimensional gait analysis to carry out accurate functional test..This project will explore the central strategy of ACL postoperative functional recovery from a new perspective, to provide a more reasonable high-level evaluation index for the timing of return to sports, and to reduce the incidence of postoperative re-tearing.


Eligibility criteria: Inclusion Criteria:

Patients who completed the same operation and completed phased home rehabilitation instruction and who underwent ACL reconstruction more than 2 years after the operation were recruited as the test subjects

Exclusion Criteria:

heart and nervous system diseases, Other sports injuries such as medial collateral ligament injury, meniscus repair, grade III-IV cartilage injury, ankle instability, metal implants in the body and medication were excluded

Primary outcomes:
measure: ALFF
timeFrame: 2 years post-operation
measure: FC
timeFrame: 2 years post-operation
Secondary outcomes:
measure: Lysholm
timeFrame: 2 years post-operation
measure: Tegner
timeFrame: 2 years post-operation
measure: COP（center of pressure ）
timeFrame: 2 years post-operation
measure: CR
timeFrame: 2 years post-operation
measure: single leg jump test
timeFrame: 2 years post-operation
measure: 6M timing single leg jump test
timeFrame: 2 years post-operation
Other outcomes:
Locations:
city: Hangzhou
country: China
facility: Hongyun song
state: Zhejiang
Study officials:
References:
Clinical trial NCT01548872: Comparison of the Effects of Crystalloid Cardioplegia and HTK Solution for Postoperative Troponin-I and CK-MB Levels After Pediatric Cardiac Surgery
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Myocardial Injury
Keywords: HTk solution
Cardioplegia
myocardial protection
pediatric cardiac surgery
Lead sponsor: Baskent University
Sponsor class: OTHER
First posted: 2012-03-08
Enrollment: 60
Sex: ALL
Minimum age (years): 1
Maximum age (years): 6
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The purpose of this study is to compare two different cardioplegia solutions effect on postoperative Troponin-I and CK-MB levels after pediatric cardiac surgery.


Eligibility criteria: Inclusion Criteria:

* Patients scheduled for elective pediatric cardiac surgery
* Patients written informed consent for study participation

Exclusion Criteria:

* redo surgery
* allergy to study drugs
* unstable blood pressure before cardiac surgery

Primary outcomes:
measure: myocardial protective effect of HTK solution
timeFrame: postoperative 48 hours
Secondary outcomes:
measure: hemodynamic and respiratory data
timeFrame: postoperative 48 hours
Other outcomes:
Locations:
city: Ankara
country: Turkey
facility: Baskent University, Faculty of Medicine
state: Çankaya
Study officials:
References:
Clinical trial NCT05004246: Longitudinal Changes in Characteristics of COVID-19 Survivors and Their Long-term Follow-up Study
Official title: Longitudinal Changes in Characteristics of COVID-19 Survivors and Their Long-term Follow-up Study
Study type: OBSERVATIONAL
Overall status: ENROLLING_BY_INVITATION
Conditions: Prognosis
Sequelae
Keywords: COVID-19
follow-up
consequences
Lead sponsor: Tongji Hospital
Sponsor class: OTHER
Collaborators: name: First Affiliated Hospital Xi'an Jiaotong University
name: Yichang Central People's Hospital
name: First Affiliated Hospital of Wenzhou Medical University
name: Xiangya Hospital of Central South University
name: Yunnan Provincial Infectious Disease Hospital
name: WUHAN Number Seven HOSPITAL
name: Shanxi Bethune Hospital
First posted: 2021-08-13
Enrollment: 1000
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: This study will enroll recovered patients with confirmed COVID-19 who were discharged from Hospital.

Brief summary: Follow-up study of Coronavirus disease 2019 (COVID-19) survivors has rarely been reported. We aimed to investigate longitudinal changes in the characteristics of COVID-19 survivors after discharge.

Detailed description: From December 2019, coronavirus disease 2019 (COVID-19), caused by a β-coronavirus known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread across the globe. Numerous studies have been performed so far to investigate clinical characteristics, risk factors, potential treatment and pathogenesis of COVID-19. However, little information is available on the long-term prognosis and possible sequelae of COVID-19 survivors who have recovered and been discharged from hospital. Hence, the investigators conducted a prospective study to investigate the long-time prognosis and the possible sequelae of COVID-19 survivors. The investigators evaluated Demographic and clinical characteristics, laboratory and radiological findings,pulmonary function tests, electrocardiogram, complications as well as treatment and symptoms and signs of COVID-19 patients.

Eligibility criteria: Inclusion Criteria:

Patients with confirmed COVID-19 who have complete hospitalization data.

Exclusion Criteria:

Suspected cases of COVID-19.

Primary outcomes:
measure: symptoms and signs
timeFrame: 1-3years
measure: SF-36 Questionnaire to the ability of Life
timeFrame: 1-3years
measure: Mental quality
timeFrame: 1-3years
measure: laboratory findings,change from baseline for blood laboratory measures
timeFrame: 1-3years
measure: Radiological findings
timeFrame: 1-3years
measure: pulmonary function
timeFrame: 1-3years
measure: Heart function
timeFrame: 1-3years
measure: Abdominal ultrasound
timeFrame: 1-3years
Secondary outcomes:
Other outcomes:
Locations:
city: Wuhan
country: China
facility: Department of infectious disease, Tongji Hospital
state: Hubei
Study officials:
References: